Revolution Medicines (RVMDW) Accumulated Expenses (2019 - 2026)

Revolution Medicines' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $192.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 96.15% year-over-year to $192.5 million; the TTM figure through Mar 2026 stood at $192.5 million (up 96.15% YoY), while the FY2025 annual figure was $58.2 million, down 39.77% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $192.5 million, up from $58.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $192.5 million in Q1 2026, with the low at $4.2 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $53.2 million (2024), against an average of $63.1 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses sank 79.21% in 2022, then surged 810.37% in 2024.
• Revolution Medicines' Accumulated Expenses stood at $29.4 million in 2022, then jumped by 153.66% to $74.7 million in 2023, then climbed by 29.35% to $96.6 million in 2024, then sank by 39.77% to $58.2 million in 2025, then surged by 230.72% to $192.5 million in 2026.
• Business Quant data shows RVMDW's Accumulated Expenses at $192.5 million in Q1 2026, $58.2 million in Q4 2025, and $154.4 million in Q3 2025.